A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

Completed · Phase 3 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Key facts

Study ID

NCT02513550

Run by

Eli Lilly and Company

People needed

1257

Starts

2015-08-01

Expected to finish

2017-08-03

Last updated by the study team

2020-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Present with chronic plaque psoriasis for at least 6 months prior to enrollment
• At least 10% BSA of psoriasis at screening and at enrollment
• sPGA score of at least 3 and PASI score of at least 12 at screening and at enrollment
• Candidates for phototherapy and/or systemic therapy
• Participant must agree to use reliable method of birth control during the study; women must continue using birth control for at least 12 weeks after stopping treatment

You may not qualify if…

• Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
• History of drug-induced psoriasis
• Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
• Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment
• Concurrent or recent use of any biologic agent
• Have participated in any study with ixekizumab
• Received a live vaccination within 12 weeks prior to enrollment
• Serious disorder or illness other than psoriasis
• Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis
• Major surgery within 8 weeks of baseline, or will require surgery during the study
• Breastfeeding or nursing (lactating) women

Where it is running

• Anaheim Clinical Trials, LLC — Anaheim, California, United States
• David Stoll, M.D. — Beverly Hills, California, United States
• Dermatology Research Associates — Los Angeles, California, United States
• Center for Dermatology and Laser Surgery — Sacramento, California, United States
• Medical Center for Clinical Research — San Diego, California, United States
• University Clinical Trials, Inc. — San Diego, California, United States
• Clinical Science Institute — Santa Monica, California, United States
• Cherry Creek Research, Inc — Denver, Colorado, United States
• Florida Academic Dermatology Centers — Coral Gables, Florida, United States
• Avail Clinical Research LLC — DeLand, Florida, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Ameriderm Research — Ormond Beach, Florida, United States
• University of South Florida — Tampa, Florida, United States
• Advanced Medical Research — Atlanta, Georgia, United States
• University Dermatology — Darien, Illinois, United States
• Deaconess Clinic Inc — Evansville, Indiana, United States
• Dawes Fretzin Clinical Research — Indianapolis, Indiana, United States
• The South Bend Clinic — South Bend, Indiana, United States
• Kansas City Dermatology, PA — Overland Park, Kansas, United States
• Heartland Research Associates — Wichita, Kansas, United States
• Dermatology Specialist — Louisville, Kentucky, United States
• Dr. Shondra Smith MD — Lake Charles, Louisiana, United States
• DermAssociates, P.C. — Rockville, Maryland, United States
• Total Skin and Beauty Dermatology Center PC — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.